Navigation Links
Varian Medical Systems Publishes 2013 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
Date:9/4/2013

owards greenhouse gas emission reduction goals.

The report outlines the governance structure that determines Varian's sustainability activities and measures performance against goals stated in 2011's inaugural report. It is divided into four key areas: environmental, health access and outcomes, safety and responsibility, and colleagues and communities. Based on internationally-recognized GRI (global reporting initiative) parameters, this year's report has received an application level 'B' rating from the GRI.

Varian's 2013 Sustainability Report is available to download at:  http://www.varian.com/us/corporate/corporate_citizenship/corporate_social_responsibility.html

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 6,350 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on '/>"/>

SOURCE Varian Medical Systems
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
2. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
3. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
4. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
5. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
6. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
7. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
8. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2012
9. Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer
10. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
11. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock through Calendar Year 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... A. Arias, M.D., Ph.D., at The University of Texas ... new superbug that caused a bloodstream infection in a ... issue of The New England Journal of Medicine ... class of highly-resistant bacteria known as methicillin-resistant Staphylococcus ... of hospital and community-associated infections. The superbug has also ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... Prevention Toolkit, a collection of resources designed to ... interacting with HIV-positive patients. The goal is ... risk and decrease the spread of HIV. ... AIDS Prevention Studies, includes proven prevention interventions for ...
... performing a hysterectomy is common practice to prevent the ... performed in 55 percent of all US women having ... article in the March/April issue of t Philadelphia, PA, ... oophorectomy) while performing a hysterectomy is common practice to ...
... with key beliefs and male monogamy , TUESDAY, March ... atheists tend to have higher IQs than those who are ... IQs also seem to make men less likely to cheat. ... fidelity than men with lower IQs, although the same association ...
... drugs in the pipeline, review finds , TUESDAY, March ... studies published in major medical journals answer the fundamental ... works best for a particular condition. , So concludes ... where experts seek to determine which available medicine is ...
... disease, CDC says, upping risks for transmitting it to others, ... one in six Americans is infected with herpes simplex virus ... of the most common sexually transmitted diseases (STDs) in the ... lifetime, causing recurrent and painful genital sores, according to the ...
... ... , , ... 9, 2010 -- More than 15.7 million women are HIV positive world-wide. In fact one ... States is diagnosed with HIV . These statistics underline the critical need for women and ...
Cached Medicine News:Health News:New study questions benefits of elective removal of ovaries during hysterectomy 2Health News:Do Liberals, Atheists Have Higher IQs? 2Health News:Do Liberals, Atheists Have Higher IQs? 3Health News:Most Drug Studies Don't Help Docs Pick Best Treatment 2Health News:Most Drug Studies Don't Help Docs Pick Best Treatment 3Health News:Herpes Infects One in Six in U.S. 2Health News:Herpes Infects One in Six in U.S. 3Health News:Herpes Infects One in Six in U.S. 4Health News:Herpes Infects One in Six in U.S. 5Health News:March 10 is National Women and Girls with HIV/AIDS Awareness Day 2Health News:March 10 is National Women and Girls with HIV/AIDS Awareness Day 3
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
... designed specifically for posteror segment surgical procedures. ... fluid. A high pressure luer lock tubing ... 8in (20cm) long. ID - .02in (.50mm); ... with standing injections of viscoelastic fluids. 30G ...
... specifically for posteror segment surgical procedures. For ... A high pressure luer lock tubing set ... (20cm) long. ID - .02in (.50mm); OD ... standing injections of viscoelastic fluids. 30G (.30mm) ...
... Product designed specifically ... procedures.Designed for injection of ... viscous fluids. Special high ... to thinwall cannula. May ...
Medicine Products: